{"url_path":"/sec/ctxr/8-k/2026-05-08/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-053916-index.html","accession_number":"0001213900-26-053916","cik":"0001506251","ticker":"CTXR","issuer_name":"Citius Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-053916-index.html","primary_entity_key":"0001506251","primary_entity_name":"Citius Pharmaceuticals, Inc."},"word_count":294,"has_tables":true,"body_markdown":"** **\n\n**Item 1.01. Entry into a Material Definitive Agreement.**\n\n \n\nOn May 4, 2026, in connection\nwith an equity financing transaction and debt facility by Citius Oncology, Inc. (“Citius Oncology”), the majority-owned subsidiary\nof Citius Pharmaceuticals, Inc. (the “Company”), the Company and Citius Oncology entered into a Third Amendment to Promissory\nNote (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September\n10, 2025 and December 10, 2025, issued by the Citius Oncology to the Company in the original principal amount of $3,800,111 (the “Promissory\nNote”), to, among other things, (i) conform the payment and maturity provisions of the Promissory Note to the subordination agreement\nentered into by Citius Oncology in connection with its debt facility, such that the entire unpaid principal balance of the Promissory\nNote shall be payable on a date that is 91 days after the senior debt of Citius Oncology has been fully paid and the related loan and\nsecurity agreement has been terminated, (ii) eliminate all prior maturity triggers related to capital raises, issuances of debt or equity\nsecurities, or royalty-backed monetizations, (iii) prohibit prepayment of the Promissory Note in cash prior to the new maturity date,\nand (iv) add a voluntary conversion feature allowing the Company, subject to Citius Oncology’s approval, to convert all or a portion\nof the outstanding principal into shares of common stock at a conversion price equal to $0.90 per share. All other terms of the Promissory\nNote remain the same.\n\n \n\nThe foregoing description\nof the Third Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Amendment,\nwhich is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference."}